About: The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Mutations of the NPM1 gene (NPM1(mut)) are among the most common genetic alterations in acute myeloid leukemia and are suitable for minimal residual disease detection. We retrospectively investigated the prognostic impact of NPM1(mut)-based minimal residual disease detection from bone marrow for development of relapse by using a newly developed real-time polymerase chain reaction based on locked nucleic acid-containing primers in 174 patients, 155 of whom were treated within prospective protocols. The prognostic value of 5 cutoff values after completion of treatment or after allogeneic transplantation was studied by using cause-specific hazard models. Subsequent validation using cross-validated partial likelihood analysis revealed that an increase of more than 1% NPM1(mut)/ABL1 was most prognostic for relapse after chemotherapy, whereas an increase of more than 10% NPM1(mut)/ABL1 was most prognostic for relapse after allogeneic transplantation. Univariate and multivariate analysis of disease-free survival and overall survival revealed a significantly worse outcome in patients with >1% NPM1(mut)/ABL1 and >10% NPM1(mut)/ABL1, respectively, which remained significant after adjustment for FLT3-internal tandem duplication status. Our results in a large data set define and optimize cutoff values for early diagnosis of molecular relapse. These results may be especially important for defining triggers for early therapeutic intervention.
  • Mutations of the NPM1 gene (NPM1(mut)) are among the most common genetic alterations in acute myeloid leukemia and are suitable for minimal residual disease detection. We retrospectively investigated the prognostic impact of NPM1(mut)-based minimal residual disease detection from bone marrow for development of relapse by using a newly developed real-time polymerase chain reaction based on locked nucleic acid-containing primers in 174 patients, 155 of whom were treated within prospective protocols. The prognostic value of 5 cutoff values after completion of treatment or after allogeneic transplantation was studied by using cause-specific hazard models. Subsequent validation using cross-validated partial likelihood analysis revealed that an increase of more than 1% NPM1(mut)/ABL1 was most prognostic for relapse after chemotherapy, whereas an increase of more than 10% NPM1(mut)/ABL1 was most prognostic for relapse after allogeneic transplantation. Univariate and multivariate analysis of disease-free survival and overall survival revealed a significantly worse outcome in patients with >1% NPM1(mut)/ABL1 and >10% NPM1(mut)/ABL1, respectively, which remained significant after adjustment for FLT3-internal tandem duplication status. Our results in a large data set define and optimize cutoff values for early diagnosis of molecular relapse. These results may be especially important for defining triggers for early therapeutic intervention. (en)
Title
  • The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
  • The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML (en)
skos:prefLabel
  • The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
  • The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML (en)
skos:notation
  • RIV/00216208:11120/13:43907993!RIV14-MSM-11120___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • N
http://linked.open...iv/cisloPeriodika
  • 1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 84795
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11120/13:43907993
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • diagnosis; abnormalities; adult patients; normal karyotype; cytoplasmic nucleophosmin; gene-mutations; polymerase-chain-reaction; acute myelogenous leukemia; acute myeloid-leukemia (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • US - Spojené státy americké
http://linked.open...ontrolniKodProRIV
  • [6F5E2FA533BC]
http://linked.open...i/riv/nazevZdroje
  • Blood
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 122
http://linked.open...iv/tvurceVysledku
  • Kozák, Tomáš
http://linked.open...ain/vavai/riv/wos
  • 000321909300015
issn
  • 0006-4971
number of pages
http://localhost/t...ganizacniJednotka
  • 11120
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software